Orga**ids
Grown from Patient Tumors to
Help with Cancer Drug Selection
[IMG]http://cdn.medgadget.com/wp-content/uploads/2015/05/orga**ids-for-drug-screening.jpg[/IMG]
Since accurately picking ***** to fight patients’ unique tumor mutations remains in large part a guessing game, researchers have been working on finding better approaches. An international team of investigators has developed a way of growing living
Orga**ids from patients’ own tumor cells for use as a testing platform to discover which ***** work before trying them directly on the patients.
Orga**ids resemble the original
Tumors much better than cell lines, having a 3D structure, a variety of cells, and similar growth characteristics. In the study published in journal
Cell, the researchers grew
Orga**ids from colorectal
Cancer biopsies taken
from 20 patients. They sequenced the DNA of the
Orga**ids as well, as well as the original tumors, comparing how the pairs change over time. They discovered that similar mutations occur in the cancers and their corresponding orga**ids, pointing to the use of
Orga**ids as an*accurate platform for
Drug selection.
Some details
from the study abstract:
In Rspondin-based 3D cultures, Lgr5 stem cells from*multiple organs form ever-expanding epithelial Orga**ids that retain their tissue identity. We report the establishment of tumor orga**id cultures from 20 consecutive colorectal carci**ma (CRC) patients. For most, Orga**ids were also generated from adjacent **rmal tissue. Orga**ids closely recapitulate several properties of the original tumor. The spectrum of genetic changes within the “living biobank” agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor Orga**ids are amenable to high-throughput Drug screens allowing detection of gene-drug associations. As an example, a single orga**id culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than inAPC. Orga**id tech**logy may fill the gap between Cancer genetics and Patient trials, complement cell-line- and xe**graft-based Drug studies, and allow personalized therapy design.
Study in journal*
Cell:
Prospective Derivation of a Living Orga**id Biobank of Colorectal Cancer Patients…
Source:
Cell Press…
The post
Orga**ids Grown from Patient Tumors to Help with Cancer Drug Selection appeared first on
Medgadget.
